Press release
Future Directions in CD47 Research: Innovations and Clinical Translation
CD47, a protein that plays a critical role in immune evasion by tumor cells, has emerged as a key target in cancer research. Its ability to interact with signal regulatory protein alpha (SIRPα) on macrophages, delivering a "don't eat me" signal that prevents the phagocytosis of tumor cells, has made it a focal point for therapeutic development. As research into CD47 progresses, several innovative approaches and clinical translation efforts are shaping the future of cancer treatment.Download Report:
https://www.kuickresearch.com/report-cd47-antibody-cd47-inhibitor-cd47-function-cd47-expression-cd47-t-cells-cd47-marker-anti-cd47-antibody
One of the most promising directions in CD47 research is the development of next-generation antibodies and therapeutic agents. While first-generation CD47-targeting antibodies have shown success in early clinical trials, there is ongoing work to enhance their specificity, reduce off-target effects, and improve patient outcomes. Innovations in antibody engineering, such as the development of bispecific antibodies that target both CD47 and another tumor-associated antigen, are being explored to increase the efficacy of treatment and minimize adverse effects. These bispecific antibodies are designed to selectively bind to CD47 on tumor cells while sparing healthy cells, thus reducing the risk of side effects like anemia.
Another area of innovation involves the use of small molecules and peptide-based inhibitors to target the CD47-SIRPα interaction. These smaller therapeutic agents may offer advantages over monoclonal antibodies, such as better tissue penetration and oral bioavailability. Researchers are investigating the potential of these agents to disrupt the CD47-SIRPα signaling pathway more efficiently, providing new options for patients who may not tolerate antibody-based therapies.
The integration of CD47-targeting therapies with other treatment modalities is also a significant focus of current research. Combining CD47 blockade with immune checkpoint inhibitors, chemotherapy, or radiation therapy has shown synergistic effects in preclinical studies, leading to enhanced tumor regression and improved survival rates. Clinical trials are ongoing to evaluate the effectiveness of these combination therapies in various cancer types, with the goal of developing more comprehensive and effective treatment regimens.
In addition to therapeutic development, there is growing interest in the use of CD47 as a biomarker for patient stratification and treatment monitoring. As CD47 expression varies across different cancer types and patient populations, measuring its levels could help identify patients who are most likely to benefit from CD47-targeting therapies. Furthermore, tracking changes in CD47 expression during treatment could provide insights into treatment efficacy and the potential for resistance, allowing for more personalized and adaptive treatment strategies.
The clinical translation of CD47 research also extends to the exploration of its role in other diseases beyond cancer. CD47 is involved in various physiological processes, including tissue repair and immune regulation, making it a potential target for treating conditions such as autoimmune disorders and chronic inflammatory diseases. Research in these areas is still in its early stages, but the potential applications of CD47-targeting therapies could extend far beyond oncology.
As CD47 research continues to advance, the future of cancer therapy looks increasingly promising. The innovations in therapeutic development, coupled with a deeper understanding of CD47's role in disease, are paving the way for more effective and less toxic treatments. With ongoing clinical trials and new approaches on the horizon, CD47-targeting therapies are poised to make a significant impact on the treatment landscape, offering new hope to patients with challenging and resistant cancers.
KuicK Research
Delhi
India
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Future Directions in CD47 Research: Innovations and Clinical Translation here
News-ID: 3651102 • Views: …
More Releases from KuicK Research

Multispecific Antibodies Clinical Trials By Indication Country Company Drug Clas …
Global Multispecific Antibodies Market, Drug Sales, Dosage, Price and Clinical Trials Insight 2030 Report Highlights:
• Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion
• Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion
• Number Of Approved Multispecific Antibodies: 18
• Global and Regional Trends Insight
• Approved Antibodies Global, Regional, Annual and Quarterly Sales Insight
• Approved Antibodies Dosage and Pricing Insight
• Comprehensive Insight On All Antibodies In Clinical…

Gamma Delta T Cell Cancer Therapy Market Opportunity Clinical Trials Technology …
Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions:
• Number Of Gamma Delta T Cell Therapies In Trials: > 30 Therapies
• US & China Dominating Clinical Trials Landscape: > 20 Therapies
• Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
• Gamma Delta T Cell Therapy Future Market Opportunity By Different Cancers
• Insight On Clinical Platforms for Evolving…

US Orphan Drugs Market Sales Clinical Trials Insight 2030
US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights:
• US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030
• Insight On FDA Designated Orphan Drugs In Clinical Trials: > 850 Orphan Drugs
• Clinical Trials Insight By Company, Indication, Phase and Priority Status
• Insight On FDA Designated Marketed Orphan Drugs: > 500 Orphan Drugs
• Pricing and Dosage Insight: > 400 Marketed Orphan Drugs
• US, Global,…

US Orphan Drug Market Size Forecast 20230
US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights:
• US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030
• Insight On FDA Designated Orphan Drugs In Clinical Trials: > 850 Orphan Drugs
• Clinical Trials Insight By Company, Indication, Phase and Priority Status
• Insight On FDA Designated Marketed Orphan Drugs: > 500 Orphan Drugs
• Pricing and Dosage Insight: >…
More Releases for CD47
CD47 Targeting Therapeutics Market Robust Expansion is expected to 2034
CD47 Targeting Therapeutics Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By…
CD47 Targeting Therapeutics Market Investments, Share and Revenue Analysis Repor …
CD47 Targeting Therapeutics Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By…
CD47 Targeting Therapeutics Market Future Trends and Scope Analysis Report
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type of Molecule (Biologics and Small Molecule), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
According to…
CD47 Targeting Therapeutics on Target A Multi-Billion Dollar Market Revolutioniz …
CD47 Targeting Therapeutics Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type…
CD47 Targeting Therapeutics Market Future Trends and Scope Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By Type of molecule(Biologics, Small molecule) - Market Outlook and Industry Analysis 2030"
According to the latest research…
CD47 Targeting Therapeutics Market to Record an Exponential CAGR by 2030
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type of Molecule (Biologics and Small Molecule), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Request for…